Stephen M. Dunn

Mr. Dunn is currently President and Senior Managing Director of Healthcare at LifeTech Capital, a life sciences business development firm. Previously, he was Senior Managing Director of LifeTech Capital Healthcare Investment Banking at Aegis Capital and Newbridge Securities. Prior to those positions, Mr. Dunn was Senior Managing Director of LifeTech Capital Research at Newbridge Securities, Aurora Capital and Jesup & Lamont, as well as Director of Research at Dawson James Securities. Mr. Dunn was a top ranked 5-star biotechnology analyst on Thomson Reuters StarMine and he holds Series 7, 63, 24, 86, 87 and 79 securities licenses (currently inactive).

Prior to Mr. Dunn’s career on Wall Street, he worked at several public and private global biomedical companies working in over 25 countries in North America, Europe and the Far East. He has held management positions in Business Development, Finance and Operations, most recently in business development at Coulter Corporation and Beckman Coulter (acquired by Danaher). He previously held various management positions at Telectronics (acquired by St. Jude Medical and now Abbott Laboratories), Cordis Corporation (acquired by Johnson & Johnson and now Cardinal Health) as well as several smaller companies within the biomedical industry. He has negotiated numerous intellectual property licenses as well as product development, venture funding, M&A and joint venture agreements.

Mr. Dunn is an accomplished speaker and moderator at both financial and scientific conferences and has appeared in financial publications such as the Wall Street Journal, Barron’s the Washington Post and the Financial Times and in scientific publications such as Nature and The Scientist as well as on television for the Nightly Business Report and Bloomberg.